Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1998-1-13
|
pubmed:abstractText |
Up to now there has been no routinely used and easy-to-perform method for the quantification of bone uptake. Therefore, we have evaluated the clinical practicability of a new and simple method for the measurement of bone uptake based upon conventional three-phase bone scanning. In 13 patients with normal bone scans, whole-body scintigrams were obtained at 3 min and 1, 2, 3, 4, 5, 6 and 24 h after injection of 600 MBq technetium-99m hydroxymethylene diphosphonate (HMDP). Using a conventional region of interest technique, fitted time-activity curves of soft tissue and urinary excretion were established, and bone uptake was calculated from these data as the total whole-body activity minus both soft tissue activity and urinary excretion. Subsequently, the new method was tested in routine patient management: 32 healthy patients and five patients with different types of metabolic bone disease were investigated, measurements being performed only at 3 min and 3-4 h p. i. during conventional three-phase bone scanning. In the multi-imaged patient subset, soft tissue activity decreased exponentially, reaching a plateau after 6 h with a residual activity of about 14% of initial total whole-body activity. Bone uptake reached quite a stable plateau of about 27% as early as 3 h p.i., with no significant changes up to 24 h. Healthy patients of the two-scan group showed no differences in bone uptake (mean uptake values were 24.1% in women and 26.9% in men), whereas in patients with metabolic bone disease bone uptake was significantly higher, with a mean of 48% (P <0.05). Thus, the results of this method are in good agreement with the findings of standard 24-h whole-body retention measurements. The new method, however, is easy to perform, allows assessment of pure bone uptake instead of whole-body retention, and permits calculation of bone uptake by only two measurements during routine three-phase bone scanning.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0340-6997
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1284-90
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9323270-Adult,
pubmed-meshheading:9323270-Aged,
pubmed-meshheading:9323270-Bone Diseases, Metabolic,
pubmed-meshheading:9323270-Bone and Bones,
pubmed-meshheading:9323270-Case-Control Studies,
pubmed-meshheading:9323270-Female,
pubmed-meshheading:9323270-Humans,
pubmed-meshheading:9323270-Male,
pubmed-meshheading:9323270-Middle Aged,
pubmed-meshheading:9323270-Radiopharmaceuticals,
pubmed-meshheading:9323270-Technetium Tc 99m Medronate,
pubmed-meshheading:9323270-Tissue Distribution
|
pubmed:year |
1997
|
pubmed:articleTitle |
Quantification of diphosphonate uptake based on conventional bone scanning.
|
pubmed:affiliation |
Clinic of Nuclear Medicine, Christian-Albrechts-University, Kiel, Germany.
|
pubmed:publicationType |
Journal Article
|